Lantern Pharma (NASDAQ: LTRN), a biotechnology firm utilizing its RADR(R) AI platform to fast-track the development of precision oncology drugs, has announced a strategic partnership with IBN to spearhead its corporate communications efforts. This collaboration is set to bolster investor awareness as Lantern Pharma advances its innovative, data-driven pipeline, which includes three AI-guided drug candidates and a subsidiary focused on central nervous system (CNS) therapies. The company's clinical programs target a range of cancers, such as lung, brain, breast, and blood cancers, with several therapies already in active trials and holding FDA designations.
The significance of this partnership lies in Lantern Pharma's unique approach to oncology drug development. By leveraging over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms, the company's RADR(R) platform has demonstrated the ability to reduce the time and cost associated with bringing new therapies to market. Notably, Lantern Pharma has achieved the transition from initial AI insights to first-in-human clinical trials in just 2-3 years, with an average cost of approximately $2.5 million per program. This efficiency is a game-changer in the biotech industry, where traditional drug development processes are often lengthy and expensive.
The engagement with IBN is a strategic move to communicate these advancements and milestones to investors and the broader public effectively. As Lantern Pharma continues to make strides in its mission to revolutionize oncology treatment through AI, this partnership underscores the growing intersection of technology and healthcare, highlighting the potential for AI to address some of the most challenging aspects of cancer therapy development. For more details on Lantern Pharma's innovative work and its partnership with IBN, visit https://ibn.fm/6gYcX.
